Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150874 | 1.00 | ATM (0.40) | ATMACHETAAR1KMT2AMEN1 | |
| SCHEMBL31310089 | 0.74 | TSHR (0.33) | ATMKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL20924944 | 0.72 | BRD4 (0.38) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20924990 | 0.72 | BRD4 (0.41) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL20924916 | 0.71 | ACHE (0.37) | ACHETAAR1 | |
| SCHEMBL12812176 | 0.71 | BRD4 (0.37) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12811761 | 0.71 | BRD4 (0.37) | KMT2AMEN1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21674388 | 0.71 | MAOA (0.40) | ATMKMT2AMEN1ALDH1A1GLA | |
| SCHEMBL287975 | 0.70 | ALDH1A1 (0.45) | ATMKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL8809862 | 0.68 | ALDH1A1 (0.47) | ATMKMT2AMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531616-B2 | Contacting lactone compound with an oxalate in presence of a base and a solvent to form an intermediate mixture; reacting with a formaldehyde derivative to form a product mixture; isolating alpha - substituted hydrocarbylidene lactones | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-03-11 | — | — | US | disclosed |
| US-20020143195-A1 | Process for the preparation of a-methylenelactones and a-substituted hydrocarbylidene lactones | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143195-A1 | Process for the preparation of a-methylenelactones and a-substituted hydrocarbylidene lactones | ESD, ODC1, DDT | ATM 1430/4885ACHE 320/4885TAAR1 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.